Related Experiment Video

Updated: May 4, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

5.7K

Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors

Kevin J Basile1, Kaitlyn Le, Edward J Hartsough

  • 1Department of Cancer Biology and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.

Pigment Cell & Melanoma Research
|January 16, 2014
PubMed

Insights

Next-generation RAF inhibitors, like PLX7904, show promise in treating advanced melanoma by overcoming resistance to current therapies. These new drugs effectively target BRAF V600E mutations and splice variants, offering a potential second-line treatment option.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Vemurafenib and dabrafenib are standard treatments for BRAF(V600E) melanoma but face challenges with acquired resistance and paradoxical signaling.
  • Next-generation RAF inhibitors are needed to overcome these limitations and improve patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of next-generation RAF inhibitors, PLX7904 and PLX8394, in preclinical models of melanoma.
  • To assess their ability to overcome resistance mechanisms, including NRAS mutations and BRAF splice variants.

Main Methods:

  • In vitro testing of PLX7904 and PLX8394 in BRAF(V600E) melanoma cell lines, including those resistant to vemurafenib.
  • Analysis of MEK-ERK1/2 signaling pathway, cell cycle progression, and cell survival.

Main Results:

  • PLX7904 effectively inhibits RAF signaling in BRAF(V600E) melanoma without paradoxical effects in wild-type cells.
  • PLX7904 demonstrated activity against vemurafenib-resistant cells with NRAS mutations and BRAF splice variants.
  • PLX7904 and PLX8394 potently blocked signaling and growth in cells resistant to vemurafenib/PLX4720 due to BRAF splice variants.

Conclusions:

  • Paradox-breaker RAF inhibitors like PLX7904 and PLX8394 are potent against melanoma with resistance mechanisms.
  • These agents warrant further investigation as a second-line therapy for patients with advanced BRAF(V600E) melanoma who have progressed on existing treatments.
Keywords:
BRAFParadox-breaker RAF inhibitorsplice variantvemurafenib resistance

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.9K
The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression11:02

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

Published on: August 3, 2011

51.2K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
5.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K